Key Points
- CFO Adam Laponis sold 2,738 shares on Jan. 9 at an average price of $35.26 for $96,541.88, trimming his stake by 1.92% to 140,031 shares valued at about $4.94M.
- Twist's stock recently rallied (opened $40.22) and analysts are largely positive (nine Buys vs two Sells, consensus target $44.67), even after the company missed EPS (-$0.45 vs -$0.40) while beating revenue at $99.01M.
Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) CFO Adam Laponis sold 2,738 shares of the business's stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $35.26, for a total value of $96,541.88. Following the completion of the transaction, the chief financial officer directly owned 140,031 shares in the company, valued at approximately $4,937,493.06. This trade represents a 1.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Adam Laponis also recently made the following trade(s):
- On Thursday, October 30th, Adam Laponis sold 5,517 shares of Twist Bioscience stock. The shares were sold at an average price of $31.44, for a total transaction of $173,454.48.
Twist Bioscience Stock Up 5.7%
Twist Bioscience stock opened at $40.22 on Wednesday. The company has a market capitalization of $2.46 billion, a PE ratio of -30.70 and a beta of 2.19. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $55.33. The firm's fifty day moving average is $31.82 and its 200 day moving average is $31.14. The company has a quick ratio of 3.33, a current ratio of 3.64 and a debt-to-equity ratio of 0.03.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.05). Twist Bioscience had a negative net margin of 20.63% and a negative return on equity of 27.40%. The company had revenue of $99.01 million during the quarter, compared to the consensus estimate of $97.40 million. As a group, sell-side analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of brokerages have commented on TWST. Barclays raised their price objective on Twist Bioscience from $37.00 to $39.00 and gave the company an "overweight" rating in a research note on Monday, December 15th. Stephens assumed coverage on shares of Twist Bioscience in a research report on Monday, November 3rd. They issued an "overweight" rating and a $41.00 price target for the company. Cowen restated a "buy" rating on shares of Twist Bioscience in a research note on Thursday, January 8th. TD Cowen raised their price objective on shares of Twist Bioscience from $32.00 to $43.00 and gave the company a "buy" rating in a research note on Thursday, January 8th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Twist Bioscience in a research report on Monday, December 29th. Nine analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $44.67.
Check Out Our Latest Analysis on Twist Bioscience
Hedge Funds Weigh In On Twist Bioscience
A number of hedge funds have recently bought and sold shares of TWST. Quarry LP bought a new stake in shares of Twist Bioscience in the 3rd quarter worth $28,000. Smartleaf Asset Management LLC lifted its position in shares of Twist Bioscience by 70.6% during the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company's stock valued at $29,000 after purchasing an additional 442 shares in the last quarter. National Bank of Canada FI purchased a new position in Twist Bioscience during the third quarter worth about $46,000. Mirae Asset Global Investments Co. Ltd. grew its position in Twist Bioscience by 15.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company's stock worth $85,000 after purchasing an additional 302 shares in the last quarter. Finally, Geneos Wealth Management Inc. bought a new stake in Twist Bioscience in the 2nd quarter worth about $97,000.
Twist Bioscience Company Profile
(
Get Free Report)
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
